Gut feelings: A randomised, triple-blind, placebo-controlled trial of probiotics for depressive symptoms by Chahwan, B et al.
Elsevier required licence: © <2019>. This manuscript version is made available under the CC-BY-NC-
ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/         














Journal of Affective Disorders xxx (xxxx) xxx-xxx
Contents lists available at ScienceDirect
Journal of Affective Disorders
journal homepage: www.elsevier.com
Gut feelings: A randomised, triple-blind, placebo-controlled trial of probiotics for
depressive symptoms
Bahia Chahwan ⁠a, Sophia Kwan ⁠b, Ashling Isik ⁠b, Saskia van Hemert ⁠c, Catherine Burke ⁠a⁠, ⁠⁎, Lynette Roberts ⁠b⁠, ⁠⁎
a School of Life Sciences, University of Technology Sydney, PO Box 123 Broadway, NSW 2007, Australia
b Discipline of Clinical Psychology, Graduate School of Health, University of Technology Sydney, Australia
c Winclove Probiotics, Amsterdam, the Netherlands
A R T I C L E I N F O A B S T R A C T
Background: Depression is the leading cause of disability worldwide; with evidence suggesting that decreased
gut barrier function and inflammation are correlated with depressive symptoms. We conducted a clinical trial
to determine the effect of consumption of probiotic supplements (Winclove's Ecologic® Barrier) on depressive
symptoms in a sample of participants with mild to severe depression.
Method: 71 participants were randomly allocated to either probiotic or placebo, which was, consumed daily over
eight weeks. Pre- and post-intervention measures of symptoms and vulnerability markers of depression as well
as gut microbiota composition were compared. Clinical trial participants were also compared on psychological
variables and gut microbiota composition to a non-depressed group (n=20).
Results: All clinical trial participants demonstrated improvement in symptoms, suggesting non-specific therapeu-
tic effects associated with weekly monitoring visits. Participants in the probiotic group demonstrated a signifi-
cantly greater reduction in cognitive reactivity compared with the placebo group, particularly in the mild/mod-
erate subgroup. Probiotics did not significantly alter the microbiota of depressed individuals, however, a signifi-
cant correlation was found between Ruminococcus gnavus and one depression metric.
Limitations: There was a high attrition rate, which may be attributed to weekly monitoring visits. Additionally,
modulation of the gut microbiota may need more specific testing to distinguish subtle changes.
Conclusions: While microbiota composition was similar between all groups, probiotics did affect a psychological
variable associated with susceptibility to depression. Further research is needed to investigate how probiotics can
be utilised to modify mental wellbeing, and whether they can act as an adjunct to existing treatments.
1. Introduction
Depression is a debilitating psychiatric disorder that is the leading
cause of disability world-wide (Kessler and Bromet, 2013; World Health
Organization, 2017). Multiple causes of depression have been identi-
fied, including genetic, neurological, inflammatory, personality, cogni-
tive, and environmental factors (Beck and Bredemeier, 2016; Disner
et al., 2011; Miller and Raison, 2016; Sullivan et al., 2000; Wohleb
et al., 2016). A number of different therapy modes exist, including
pharmacological treatments (e.g. antidepressant medications), and psy-
chological therapies (e.g. cognitive-behaviour therapy), which aim to
alleviate symptoms by targeting the neurological functioning or mal-
adaptive cognitive patterns affected in depression (Beck, 2002; Wallace
and Milev, 2017). Research indicates that these treatments
are effective in reducing depressive symptoms, with approximately
60–70% of patients responding to treatment (Al-Harbi, 2012). However,
an estimated third of patients do not respond to existing treatments,
and a significant number of people do not seek treatment due to the as-
sociated stigma (Collins et al., 2011; Rieder et al., 2017; Souery et al.,
1999). As such, there is need for additional or adjunctive treatment
strategies for depression.
The gut microbiota is recognised to play a significant role in human
health and disease (Gareau et al., 2010; McCusker and Kelley, 2013;
Round and Mazmanian, 2009; Sekirov et al., 2010). Its influence ex-
tends beyond the gut and has been associated with diseases including,
but not limited to, obesity (Turnbaugh et al., 2009), Type-2 diabetes
(Larsen et al., 2010), celiac disease (De Palma et al., 2010), Crohn's
disease (Scanlan et al., 2006), and depression (Jiang et al., 2015;
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Kelly et al., 2016; Lin et al., 2017; Naseribafrouei et al., 2014; Zheng
et al., 2016). A range of rodent and human studies have indicated
that disruption of the gut microbiota modulates stress reactivity (Bravo
et al., 2011; Goehler et al., 2007; Lyte et al., 2006), and is linked to
poorer mental health outcomes (Logan and Katzman, 2005; Rao et al.,
2009). Further evidence linking the gut microbiota to mental health
comes from faecal microbiota transplants (FMTs), where BALB/c mice
with a natural tendency toward anxious behaviour can be shifted to-
wards the more outgoing behaviour of NIH Swiss mice via FMT
(Bercik et al., 2011). Similarly, FMTs from depressed humans results in
the development of depressive behaviours in rodents (Kelly et al., 2016;
Zheng et al., 2016). These studies suggest that the gut microbiota exerts
a strong influence on mental health, and that manipulation of the mi-
crobiota could be a viable treatment option.
The gut microbiota may mediate effects on mental health via the
gut-brain axis, a bidirectional communication system between the gas-
trointestinal tract (GI) and the central nervous system (CNS). This axis
involves the integration of neural, hormonal and immunological signals
(Mayer et al., 2014), and has been recognised to play a role in modulat-
ing physical and psychological health(Foster and Neufeld, 2013; Mayer,
2011; Steenbergen et al., 2015). The vagus nerve has been shown to
mediate communication between the gut and brain, as antidepressant
effects of probiotics in mice are no longer observed when the vagus
nerve is severed (Bravo et al., 2011). Another possible mechanism in-
volved in gut-brain interaction are metabolites of tryptophan. Trypto-
phan can be converted into serotonin, but most of it is converted to
kynurenine, especially under inflammatory conditions. Kynurenine can
be converted further to anthranilic acid, kynurenic acid, and quinolinic
acid of which the latter two have neuromodulatory properties (Kennedy
et al., 2017; Waclawiková and El Aidy, 2018). Further, gut microbiota
may affect mental health via stimulation of systemic inflammation. Nu-
merous studies have shown that pro-inflammatory cytokines, such as
IL-6 and TNF-alpha are increased in people with depression (Cizza et al.,
2008; Dowlati et al., 2010; Lanquillon et al., 2000; Maes et al., 1995;
Mesquita et al., 2008). The cause of the increased inflammation is not
yet understood but one hypothesis is that it results from a ‘leaky gut’
(Maes et al., 2012). A leaky gut is characterised by an increase in gut
permeability through decreased barrier function, which includes the
epithelial mucus layer and complex tight junctions. This barrier pre-
vents microbes and other inflammatory stimulants from moving across
the epithelium (Arrieta et al., 2006; Turner, 2009), and different bac-
terial species have the ability to either promote or weaken this bar-
rier (Pedicord et al., 2016). When the barrier is impaired it can lead to
gut leakiness allowing microbial products such as lipopolysaccharides
(LPS) to activate an inflammatory immune response (Maes et al., 2012;
Qin et al., 2007). It is thought that systemic inflammation as a result
of leaky gut can influence brain functioning via pro-inflammatory cy-
tokines crossing the blood-brain barrier and affecting central nervous
system functioning such as serotonin signaling, contributing to symp-
toms of depression (Sampson and Mazmanian, 2015).
The concept of ‘psychobiotics’, defined as probiotics which can con-
fer mental health benefits, has emerged in recent years (Dinan et al.,
2013; Sarkar et al., 2016; Wall et al., 2014; Zhou and Foster, 2015).
Probiotics are defined as live microorganisms that provide a beneficial
health effect (Hill et al., 2014). Probiotic bacterial species have been
shown to improve gut barrier function (Krishna Rao and Samak, 2013),
and preclinical studies in animals and humans have demonstrated im-
provements in behaviour and mood with probiotic treatment (Benton
et al., 2007; Desbonnet et al., 2010; Steenbergen et al., 2015). Clini-
cal trials of probiotics for the treatment of depression have reported
conflicting results. Akkasheh and colleagues identified that consump-
tion of probiotics containing Lactobacillus acidophilus, Lactobacillus ca-
sei, and Bifidobacterium bifidum over an eight-week period led to a
significant reduction in depressive symptoms (Akkasheh et al., 2016).
Romijn et al. conducted a similar 8-week clinical trial with the probiotic
strains Lactobacillus helveticus and Bifidobacterium longum, but found no
evidence of an effect on depression (Romijn et al., 2017). Evidently, fur-
ther research is required to determine the effectiveness of probiotic con-
sumption including specific strains, dosage and duration of treatment,
and whether probiotics can function as an adjunct or standalone ther-
apy.
In this study we report the results from a randomised clinical trial
investigating the effect of regular probiotic consumption on depressive
symptoms. The primary aim of this study was to determine whether
eight-week consumption of a probiotic supplement (Winclove's Eco-
logic® Barrier) led to a reduction in depressive symptoms in a sam-
ple of participants with a range of symptom severity. As depression is
typically thought of as existing on a continuum (Ayuso-Mateos et al.,
2010), with intensity of treatment varying based on depression sever-
ity (Davidson, 2010). The primary outcome was also determined based
on the Mini International Neuropsychiatric Interview (M.I.N.I)
(Hergueta et al., 1998) clinician ratings. A secondary aim was to de-
termine whether the treatment effect varied with baseline levels of de-
pression; do individuals with milder levels of depression severity re-
spond differently to those with more severe depression to probiotic
treatment? Another secondary aim was to investigate any potential ef-
fects of the probiotics on cognitive reactivity towards sad mood. This
cognitive reactivity, thinking patterns or so-called dysfunction attitudes,
are strengthened during depressive episode (Figueroa et al., 2018) and
it has been shown earlier in healthy students that probiotic intake could
influence the patterns (Steenbergen et al., 2015). Finally, faecal samples
were taken before and after treatment to explore potential changes in
the gut microbiota and were also compared to a non-depressed control
group.
We hypothesised that probiotic treatment would reduce depressive
symptoms when compared to the placebo group, particularly for those
with milder levels of depression. For the microbiota, we expected to see
baseline differences between the depressed cohort and non-depressed
group. Additionally, we anticipated that changes in psychological scores
during the course of the clinical trial might be associated with changes
in the composition of the microbiota.
2. Method
2.1. Design
The study was a triple-blinded parallel, placebo-controlled ran-
domised clinical trial. Participant numbers were randomly allocated
into two groups (probiotic and placebo) via a computerised randomiser
in blocks of four by a researcher not directly involved with adminis-
tration of the product (S. van Hemert). Recruited participants were al-
located a participant number, with both researchers administering the
trial (L. Roberts and S. Kwan) as well as participants being unaware of
group allocation throughout the trial and analysis of the results. Sample
size calculations were based on clinical trials investigating psychologi-
cal and antidepressant therapies for depression since when the present
study was designed there were no other published clinical trials looking
at probiotics for depression to use as a comparison. Power calculations
indicated that a sample size of 26–36 participants in each group was
sufficient to detect a moderate to large between-group effect size (ES) of
0.67–0.80 with power of 80%, which was the minimum expected based
on similar studies using BDI scores as a primary outcome for treatment
of depression (Dimidjian et al., 2006; Titov et al., 2011). This study
was approved by the University of Technology Sydney Human Research
Ethics committee, UTS HREC Reference number: 2015000438. The trial
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2.2. Participants
71 participants with depressive symptoms were recruited and allo-
cated sequentially over 12 months at the University of Technology Syd-
ney (UTS), Ultimo campus, New South Wales, Australia. Potential par-
ticipants were screened through the Beck Depression Index - Second
Edition (BDI-II) (Beck et al., 1996) by the research team to verify eli-
gibility, with a cut-off score of 12 as a minimum score for entry into
the trial. Participants were eligible for the study if they were aged 18
years or above, could provide informed consent, were willing and able
to travel to UTS Ultimo campus on a weekly basis to complete ques-
tionnaires on mental wellbeing, could provide a stool sample at the
start and end of the treatment period, and not consume probiotic-rich
foods and drinks such as fermented cheeses during the trial, which may
act as a confound to investigating the effects of probiotic supplemen-
tation. Participants were required to be relatively healthy apart from
a diagnosis of depression and not be taking any medications (i.e. an-
tibiotics, antidepressants). Full inclusion/exclusion criteria can be found
in detail in the supplementary material (1.1.1). Participants were then
randomly allocated either probiotic (n=34) or placebo (n=37) treat-
ment. A summary of the demographic information for these partici-
pants can be seen in Table 1. Given the significant group difference
in the number of prior diagnoses of depression results were analysed
both with and without this variable as a covariate and the pattern of re-
sults did not change hence the data without this covariate is reported.
Table 1
Participant demographic information for three groups: depressed clinical trial participants
assigned probiotics or placebo and the non-depressed cohort.
Depressed participants
Probiotic Placebo Non-depressed








24.3 (9) 25.0 (5)
Female 61.8
(21)




67.6 (25) 65.0 (13)
Non-Caucasian ⁠a 31.2
(11)
32.4 (12) 35.0 (7)
Medical History ⁠b % (n)
Yes 44.1
(15)
25.0 (9) 20.0 (4)
No 55.9
(19)
75.0 (28) 80.0 (16)
Past Antidepressant Use % (n)
Yes 50.0
(17)
56.8 (21) 0 (0)*
No 50.0
(17)









35.1 (13) 31.5 (6)







Abdominal Conditions ⁠c% (n)
Yes 23.5 (8) 18.9 (7) 15.0 (3)
No 76.5
(26)
81.1 (30) 85.0 (17)
Smoking% (n)
Yes 20.6 (7) 29.7 (11) 10.5 (2)
No 79.4
(27)
70.3 (26) 89.5 (18)
Alcohol⁠d% (n)
Yes 5.9 (2) 13.5 (5) 0 (0)
No 94.1
(32)
86.5 (32) 100 (20)
⁎ p < .05.
a Asian, Hispanic/Latino, African/Middle Eastern, Indian/Sri Lankan, Indian, Polynesian,
Other.
b History of major surgeries, accidents or chronic conditions.
c Excludes Crohn's disease.
d Consume >2 standard alcoholic drinks per day.
e One value missing.
f Measure was not taken for non-depressed controls.
Additionally, there was no statistically significant difference between
the probiotic and placebo groups in their probiotic supplements or pro-
biotic rich food consumption prior to the intervention (ps > .05).
For the purposes of microbiota comparison between people with and
without depression, twenty participants were recruited for the non-de-
pressed control group over two months. Participants were eligible for
the non-depressed group if they endorsed a BDI-II score of 10 or be-
low and met the exclusion criteria described in the supplementary ma-
terial. Comparisons of baseline variables between the depressed and
non-depressed group showed that there were no significant differences
in participant age, gender, ethnicity, medical history, current abdominal
conditions, smoking habit, alcohol intake or weekly physical activity.
Across both the depressed and non-depressed groups, participants were
predominantly female (70%), Caucasian (67%), had no significant med-
ical history (69%) or abdominal conditions (80%), did not smoke (78%)
or consume above the recommended daily alcohol intake (92%).
2.3. Procedure
Following enrolment into the study, provision of informed con-
sent and allocation to a participant number, participants were pro-
vided with a stool sample kit one week prior to the start of the study.
At pre-intervention assessment, participants returned their stool sam-
ple, and completed psychological tests including the clinician admin-
istered M.I.N.I to determine a clinical or subclinical diagnosis of de-
pression, the Depression Anxiety Stress Scale - 21 Items (DASS-21)
(Lovibond and Lovibond, 1995), BDI-II, and Beck Anxiety Inventory
(BAI) (Beck and Steer, 1990) to assess their levels of depression and anx-
iety, and the Leiden Index of Depression Sensitivity-Revised (LEIDS-R)
(Van der Does and Williams, 2003) to evaluate participant's cognitive
reactivity, as well as demographic, and dietary questionnaires (further
details in supplementary material, 1.2). Participants were provided with
an eight-week supply of their randomly allocated probiotic/placebo sup-
plement, and information on how to prepare and consume the product
twice daily over the eight-week trial period. Participants then attended
weekly check-up appointments at UTS over the next seven weeks, and
completed the BDI-II, DASS-21 and Weekly Check-up questionnaire to
assess mood and monitor for side effects. Participants returned empty
probiotic/placebo sachets for compliance assessment. Participants re-
turned a second stool sample at week nine of the trial correspond-
ing to the day of or day after their last probiotic treatment. They also
completed the M.I.N.I, BDI-II, DASS-21, BAI and LEIDS-R, as well as
the post-assessment questionnaire, dietary questionnaire, and client sat-
isfaction questionnaire. Participants returned to the UTS campus one
month later to complete a follow-up assessment, where they were re-ad-
ministered the M.I.N.I, BDI-II, DASS-21, BAI and LEIDS-R, as well as the
dietary, and follow-up questionnaires.
2.4. Materials - Intervention
Participants randomly assigned to the probiotic group were provided
two sachets for each day of the trial, containing 2g of freeze-dried
probiotic powder mixture (Ecologic®Barrier; Winclove probiotics, The
Netherlands). This product has been shown before to influence de-
pressive like behaviour in rats (Abildgaard et al., 2017b, 2017a), to
influence cognitive reactivity towards sad mood (Steenbergen et al.,
2015) and to improve working memory under stress (Papalini et al.,
2019). Ecologic®Barrier (2.5×10⁠9 CFU/g) is constituted of the fol-
lowing nine bacterial strains: Bifidobacterium bifidum W23, Bifidobac-
terium lactis W51, Bifidobacterium lactis W52, L. acidophilus W37, Lac-
tobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius
W24, Lactococcus lactis W19 and Lactococcus lactis W58 (total cell count
1×10⁠10 CFU/day). With the application of new molecular identifi-
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sequencing), the declaration of bacterial strains has been updated com-
pared to previous publications. It has been confirmed that the probiotic
formulation has always contained these nine strains, and has not been
changed in ratio or CFU count since it has been (commercially) avail-
able. Participants in the placebo group were provided with two 2g sa-
chets daily of the freeze-dried maize-starch and maltodextrins, which is
the medium used to carry the probiotics in the product Ecologic®Bar-
rier. The taste, smell and colour of the placebo was identical to that of
the probiotic, but did not contain any probiotic bacteria.
2.5. Psychological data analysis
Analysis of psychological data from the clinical trial was intention
to treat, with last value brought forward (LVBF) used for post-treat-
ment outcomes. Analysis of covariance (ANCOVA) were conducted with
group (probiotics, placebo) as the between-subjects variable, post-treat-
ment (LVBF) scores as the dependent variable, and pre-treatment scores
included as a covariate. Any skewed variables were log⁠10 transformed.
Statistical analyses were conducted using IBM SPSS statistics, version 21
(Armonk, NY) (IBM Corp, 2012).
2.6. Microbiome analysis procedures
Stool samples from all participants were kept on ice or in refrigera-
tion storage before being delivered to research staff. Participants were
instructed to keep the sample in the fridge from the time of collection
until they bought the sample back to UTS. They were asked to use a
cold pack to transport the samples, but this was not provided. Upon re-
ceipt, samples were placed at 4 °C, and were then aliquoted and stored
at −80 within several days. Individual aliquots were defrosted for pro-
cessing and any remaining sample within the aliquot was then disposed
of. DNA extraction was carried out using the PowerFecal DNA Isolation
Kit, manufactured by MoBio. The methodology of extraction was com-
pleted following the manufacturer's protocol with samples defrosted and
weighed to 0.25 g prior to DNA extraction.
The 16S rRNA gene V3-V4 region was amplified from DNA sam-
ples and prepared for Illumina sequencing using a 2 stage PCR dual-in-
dexing protocol (supplementary material, 1.4.2). Negative controls were
processed at each stage of each procedure including DNA extraction and
PCR and were sequenced along with the samples, and a mock com-
munity sequencing control (ZymoBIOMICS microbial community DNA
standard by Zymo Research). The pooled library was sequenced on an
Illumina MiSeq using a V3 600 cycle kit and paired 300bp sequences
from either end of the amplicon.
The QIIME 1.9.1 pipeline (Caporaso et al., 2010) was utilised for de-
multiplexing, assigning sequences to samples and quality filtering. Ad-
ditionally, operational taxonomic units (OTUs) (used as a proxy for bac-
terial species) were clustered at 97% similarity using the pick_open_ref-
erence.py script against the GreenGenes database (DeSantis et al., 2006)
with parameters specifying the RDP classifier algorithm (Wang et al.,
2007) trained on the GreenGenes database for taxonomy assignment.
Chimeric sequences were identified and removed prior to further se-
quence processing. Samples were rarefied to an equal sequence depth
of 28,170 sequences for statistical comparisons of alpha and beta di-
versity. The OTU table was filtered to the top 100 most abundant
OTUs to increase statistical power for test of differential relative abun-
dance and correlation to the BDI, DASS-21 and LEIDS-R measures,
as has been applied in similar studies (Naseribafrouei et al., 2014).
The Kruskal Wallis test was used to determine significant differences
in relative abundance of individual taxa between groups, with the
False Discovery Rate (FDR) correction for multiple testing. Spearman's
Correlations (with FDR correction for multiple testing) were calcu-
lated to determine significant correlation of the relative abundance
of individual OTUs or taxa to the BDI, cognitive
reactivity and DASS scales for depression, anxiety and stress. Further
details on DNA sequence processing are provided in the supplemen-
tary materials (1.4.4). Quality filtered DNA sequence data has been de-
posited in the European Nucletide Archive under study accession num-
ber PRJEB30099.
The R environment (R Core Team, 2016) and the Phyloseq package
(McMurdie and Holmes, 2013) were used to calculate alpha and beta di-
versity as well as Principal Coordinates Analysis (PCoA) Three alpha di-
versity metrics (Richness, Chao1, Shannon) were calculated and differ-
ences between groups tested with the Wilcoxon Rank Sum test (R base
stats package). Beta diversity was calculated using weighted Unifrac
distances (Lozupone et al., 2011), which were used for PCoA. Differ-
ences between groups were tested with Permutational Analysis of Vari-
ance (PERMANOVA) (Anderson, 2001) as implemented in the adonis
function in the Vegan package (Oksanen et al., 2017). The Dplyr pack-
age (Wickham and Francois, 2015) was used for data manipulation and
graphs produced with the ggplot2 package (Wickham, 2009).
3. Results
3.1. Clinical trial–psychological data
The attrition rate was 34% (24/71 participants), further the details
of this and the study design can be seen in Fig. 1. The attrition rate was
calculated based on the number of participants who attended the week
9 post-intervention assessment. Further details on attrition distribution
can be found in supplementary material (2.4) Psychological data was
analyzed for 71 participants, as data analysis was intention-to-treat as
described in the previous section. The most commonly reported side ef-
fect in the probiotic group was nausea (11/34) and the most common
in the placebo group was dehydration (9/37). The probiotics group re-
ported significantly more drowsiness (20.6%) compared to the placebo
group (p = .02). There was a trend for participants in the placebo group
to report dry mouth (13.5%) more than those in the probiotics group
(p=.06). For further details on the side effects refer to Supplemen-
tary Table 1 in the supplementary material (1.1.3). Participants reported
these side effects were temporary and occurred early on in the study,
subsided quickly, and did not interfere with their ability to complete the
clinical trial.
3.2. Primary outcomes
Analysis of 71 participants using LVBF revealed no significant main
effect of group (ps > 0.05) for BDI, DASS, and BAI. . See Table 2 for
means and standard deviations for the BDI. See Supplementary Table 4
for test statistics and exact significance values for between-group analy-
ses.
The sample was split into two groups based on initial depression
severity on the BDI-II; mild/moderate (scores from 12 to 28) and severe
(scores >28). An ANCOVA revealed no significant main effect of group
(probiotics, placebo) in either the mild/moderate or severe subgroups
(ps > 0.05). See Table 3 for means and standard deviations. See Sup-
plementary Table 5 for test statistics and exact significance values for
sub-group analyses.
Scores on the clinician administered psychiatric interview, the
M.I.N.I were next analyzed to determine whether there were any
changes in the number of participants with no depression diagnosis, a
subclinical depression diagnosis or a clinical depression diagnosis, be-
fore and after intervention, and one month follow-up, by group alloca-
tion. Friedman Tests (non-parametric alternatives to one-way ANOVA
with repeated measures) indicated that there was a statistically sig-
nificant difference in the level of clinical diagnoses (none, subclinical,
clinical) across time points in the probiotics, but not placebo group,
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Fig. 1. Flow chart of the study design. 71 participants were recruited for the clinical trial, and 20 non-depressed controls were recruited separately for the purposes of microbiota com-
parison. For depressed participants the attrition rate was 34%.
Post hoc analysis with Wilcoxon signed-rank tests was conducted with
a Bonferroni correction applied, resulting in a significance level set
at p < .017. There was no significant difference in clinical diagnoses
between pre and post in the probiotics group (Z=−2.31. p=.02),
however there were significant differences between pre and follow-up
(Z=−3.29. p=.00), and post and follow-up, (Z=−2.64. p=.00)
within the probiotics group. Over these time points participants in the
probiotics group moved from a median rank of a subclinical diagnosis
to a median rank closer to no diagnosis.
Subgroup analyses indicated that there was a statistically signifi-
cant difference in the level of clinical diagnoses (none, subclinical, clin-
ical) across time points in the severe probiotics group (χ2(2)=15.55,
p=.00), but not in the mild/moderate probiotics group (χ2(2)=3.85,
p=.15), the mild/moderate placebo group (χ2(2) = 0.15, p=.93),
or the severe placebo group (χ2(2)=0.77, p=.68). Post-hoc analy-
ses were conducted as described above and indicated a significant
difference for the severe probiotics group in the level of clinical di-
agnosis between pre and follow-up tests (Z=−2.89. p=.00), but not
between pre and post (Z=−2.12. p=.03), or post and follow-up
(Z=−2.27. p=.02). From pre to follow-up participants in the severe
probiotics group moved from a median rank of a clinical diagnosis to a
median rank of subclinical diagnosis. See Table 4 for frequency data.
3.3. Secondary outcomes
Means and standard deviations for all 71 participants using LVBF
secondary outcomes (DASS scales, Cognitive Reactivity, BAI) are re-
ported in Tables 2 and 3. We examined whether there were group
differences on cognitive reactivity scores, which are a vulnerability
marker for depression. One pair of values was missing, as the partic-
ipant did not complete the measure in its entirety at baseline. Par-
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Table 2
Psychological measures for pre and post 8-week intervention and one month follow up for
depressed participants.
Probiotic Placebo
BDI pre⁠a 28.91 (10.10) 27.97 (9.79)
BDI post 19.88 (13.44) 19.25 (11.96)
BDI follow-up 18.50 (12.40) 19.42 (12.40)
DASS depression pre 22.88 (9.96) 20.43 (10.76)
DASS depression post 15.18 (11.03) 12.97 (9.34)
DASS depression follow-up 14.53 (11.22) 13.08 (10.57)
DASS anxiety pre 12.29 (8.62) 13.51 (10.15)
DASS anxiety post 6.94 (9.25) 8.81 (7.45)
DASS Anxiety follow-up 7.35 (9.36) 9.08 (8.80)
DASS stress pre 22.82 (10.61) 21.49 (8.60)
DASS stress post 15.29 (12.42) 14.16 (11.12)
DASS stress follow-up 14.65 (11.73) 15.51 (11.85)
Cognitive Reactivity pre ⁠a 63.94 (19.90) 66.68 (16.98)
Cognitive Reactivity post 55.24 (21.64)* 61.22 (13.86)
Cognitive Reactivity follow-up 52.91 (22.51) 60.49 (16.40)
BAI pre 17.94 (11.56) 18.03 (9.80)
BAI post 12.59 (11.27) 13.84 (9.11)
BAI follow-up 11.82 (11.19) 14.16 (11.40)
⁎ p < .05.
a One pair of values missing. BDI – Beck Depression Index, DASS – Depression Anxiety Stress
Scale, BAI – Beck Anxiety Index. Results reported as Mean (SD).
scores following intervention than those in the placebo group
(F(1,67) = 4.21, p = .04, seen in Table 2. Subgroup analyses revealed
that participants in the mild to moderate severity range at baseline re-
ported lower cognitive reactivity scores following intervention, while
participants in the severe range did not (F(1,30) = 7.89, p = .01, and
F(1,33)=0.02, p=.89 respectively). This result can be seen in Table 3,
denoted by an asterisk.
There was no significant main effect of group on anxiety (BAI), or on
the depression, anxiety, stress scale scores on the DASS-21 (ps > 0.05).
There was also no effect of group (probiotics, placebo) within the sub-
group analyses (mild/moderate, severe) on either the BAI or DASS-21,
(ps > 0.05).
3.4. One-month follow-up analyses
Analyses of one-month follow-up data revealed no significant be-
tween group differences on follow-up versus post data on BDI, BAI, cog-
nitive reactivity and DASS scores (ps > 0.05). There were also no dif-
ferences between groups on the BDI, BAI, and DASS when conduct-
ing subgroup analyses. The follow-up M.I.N.I analysis has previously
been discussed in the aforementioned primary outcomes section. In-
terestingly, when conducting subgroup analyses for cognitive reactiv-
ity scores, there was a trend, where participants in the severe (but not
mild/moderate group) group who received probiotics reported lower
cognitive reactivity scores at one month follow-up compared to post-test
scores, relative to those consuming the placebo (F(1,34) = 0.3.69,
p = .06). However, this trend disappears when controlling for the num-
ber of previous diagnoses of depression (F(1,32) = 2.15, p = .15).
3.5. Clinical trial–microbiota data
43 participants provided both a pre and post stool sample, which
resulted in microbiota data that passed quality filtering. Of these, 22
were from the probiotic group and 21 from placebo. Details of gen-
eral sequencing results are provided in the supplementary material
(2.1). Overall, no significant differences were detected between groups
for participant demographics or the M.I.N.I, BDI-II, DASS-21, BAI and
LEIDS-R psychological test scores before treatment (ANOVA,
ps > 0.05).
Within the microbiota, no significant differences were found for
alpha diversity (number of distinct taxa, Wilcoxon Rank Sum
Table 3
Psychological test scores for pre and post probiotic or placebo treatment for depressed par-
ticipants and one month follow up, split into groups based on BDI severity.
Probiotic Placebo Probiotic Placebo
Mild/Moderate Mild/Moderate Severe Severe
Number 15 18 19 18






















































































Two groups based on initial depression severity on the BDI-II. The sample was split into mild/
moderate severity (scores from 12 to 28) and severe (scores >28).
An ANCOVA revealed no significant main effect of group (probiotics, placebo) in either the mild/
moderate or severe subgroups for BDI, DASS or BAI scores, ps > 0.05.
BDI – Beck Depression Index, DASS – Depression Anxiety Stress Scale, BAI – Beck Anxiety
Index. Results reported as Mean (SD).
⁎ p < .05.
Table 4




No Diagnosis 20.6 (7) 27.0 (10)
Subclinical 38.2 (13) 40.5 (15)
Clinical 41.2 (14) 32.4 (12)
After Treatment% (n)
No Diagnosis 32.4 (11) 29.7 (11)
Subclinical 38.2 (13) 45.9 (17)
Clinical 29.4 (10) 24.3 (9)
One Month Follow Up% (n)
No Diagnosis 50.0 (17) 35.1 (13)
Subclinical 32.4 (11) 40.5 (15)
Clinical 17.6 (6) 24.3 (9)
test ps > 0.05) or beta diversity (community composition, PER-
MANOVA test ps > 0.05) between the pre and post treatment samples
within both placebo and probiotic groups, or between groups.
Tests for differential relative abundance of bacterial taxa also found
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treatment time-points (Kruskal Wallis, ps > 0.05). Similarly no signifi-
cant differences were detected between time-points within each group
(Kruskal Wallis, ps > 0.05).
3.6. Relative abundance of genera contained in the probiotic treatment
To determine if the bacterial taxa in the probiotic treatment could
be detected in the gut microbiota, the relative abundance of the gen-
era consistent with those in the probiotic mixture used in the trial, Bi-
fidobacteria, Lactobacillus and Lactococcus, were compared in pre and
post treatment samples for the probiotic treatment group. After probi-
otic treatment no significant difference was detected for the Lactobacil-
lus genus and Bifidobacteria genus (Wilcoxon Rank Sum test ps > 0.05).
The Lactococcus genus was not detected in the 16S rRNA gene data and
therefore significance could not be tested.
3.7. Comparisons between depressed and non-depressed groups
The psychological data for both the depressed and non-depressed
groups can be found in the supplementary material (2.2 Table 3). As ex-
pected, participants in the depression group showed significantly higher
mean scores on measures of depression, anxiety, stress and cognitive
reactivity, as measured by BDI-II, BAI-II, DASS-21 Depression, Anxiety
and Stress subscales, and LEIDS-R. Additionally, healthy participants
were confirmed to be in the normal ranges for these psychological tests.
For the comparison between depressed and non-depressed gut mi-
crobiota, faecal samples from the clinical trial participants prior to start-
ing either probiotic or placebo treatment were compared to samples
from the 20 non-depressed participants. Three of the 71 enrolled par-
ticipants were removed from this comparison as they did not provide a
stool sample (n=1) or had low sequence coverage (n=2). Therefore, a
total of 68 depressed participants were included.
The gut microbiota for all participants was dominated by two phyla,
the Bacteroidetes (total mean 47.42% ± 17.63) and Firmicutes (total
mean 49.66 ± 14.96). However, there were no significant differences
in the relative abundance between groups at any taxonomic level. No
significant differences were found in alpha diversity (Wilcoxon Rank
Sum, p > .05). Similarly, no significant difference in community com-
position (beta diversity) (PERMANOVA, p > .05) was found between
the depressed and non-depressed groups.
The depressed cohort was then subdivided based on BDI severity
levels into two groups corresponding to severe (BDI > 28, n=36) and
mild/moderate (BDI = 12–28, n=31). No significant differences were
detected between controls and any of the severity levels of depression
for alpha diversity, beta diversity, or the relative abundance of any taxa.
Additionally, no significant differences were found between the two de-
pressed sub-groups (Kruskal Wallis, ps > 0.05).
The relative abundance of OTUs and bacterial taxa were compared
to psychological test scores using Spearman's correlation. An OTU clas-
sified as Ruminococcus gnavus (OTU ID = 360015) had a significant
(Spearman's correlation p = .04) and positive correlation (0.37) to the
DASS depression score. The relative abundance of this OTU was low
with a maximum of 2.79% of sequences per sample. This OTU was pre-
sent in 72% of the depressed participants compared to only 25% of
non-depressed, and was found in higher relative abundance in the se-
vere BDI range of depression (mean relative abundance 0.33 ± 0.72)
compared to both the mild/moderate depressed range (mean relative
abundance 0.13 ± 0.42) and the non-depressed group (mean relative
abundance 0.0041 ± 0.013) (Fig. 2).
Fig. 2. Scatter plot of the relative abundance of an OTU identified as R. gnavus with cor-
responding DASS depression scores.
4. Discussion
In this study we investigated the effectiveness of the multispecies
probiotic Ecologic® Barrier for reducing symptoms in adults with mild
to severe levels of depression. This study was built on emerging lit-
erature linking the gut microbiota with mental wellbeing and exam-
ined the utility of probiotics as a potential mechanism to improve men-
tal health. Overall, all participants across both probiotic and placebo
groups exhibited a reduction in depressive symptoms over the time-pe-
riod of the trial; levels of depression as measured through BDI-II scores
were found to have decreased between pre-intervention and post-inter-
vention assessment. These results suggest that the routine involved with
daily preparation and consumption of the probiotic and scheduled ap-
pointments, as well as involvement in these behaviours with the aim of
seeking improvement in depressive symptoms had positive impacts on
mood, irrespective of whether the probiotic or placebo was consumed.
This is in line with the evidence suggesting that routines and engage-
ment in planned activities is beneficial for reducing symptoms of depres-
sion (Cuijpers et al., 2007), which forms the basis of activity scheduling
as a component of CBT for depression (Veale, 2008).
In contrast to our hypotheses, the probiotic group did not demon-
strate greater levels of reduction in depressive symptoms compared to
the placebo group. Similarly, there was no significant difference in the
number of participants with clinical and sub-clinical diagnoses of de-
pression between the two groups at post-intervention assessment. These
findings indicate that these probiotics alone are not an effective treat-
ment option for symptom reduction, with any positive effect equal to
that produced by the placebo. Similar results were observed for mea-
sures of anxiety and stress. Further analysis was conducted after sepa-
rating participants into mild/moderate and severe levels of depressive
symptoms at pre-intervention assessment. Again, no significant differ-
ences between groups were observed in measures of depression, anxiety,
or stress at any level of severity.
However, a significant effect was observed between the probiotic
and placebo groups, particularly in the mild/moderate depression sever-
ity subgroup on a measure of cognitive reactivity towards sad mood,
which is a vulnerability marker of depression (Kruijt et al., 2013;
Steenbergen et al., 2015; Van der Does, 2005). Participants in the pro-
biotic group reported lower cognitive reactivity after the intervention
compared to the placebo group. Subgroup analysis revealed that par-
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probiotics reported lower cognitive reactivity scores following interven-
tion compared to those in the placebo group. This effect was not seen
in participants with severe levels of depression. This is consistent with
work by Steenbergen and colleagues, where probiotic supplementation
was associated with positive effects on cognitive reactivity in a sample
of non-depressed individuals. Results from the current study provides
further evidence that some probiotic mixtures can influence thinking
and cognition (Steenbergen et al., 2015). Although probiotics did not
appear to have had a direct effect on depressive symptoms, our results
suggest that probiotics potentially act on cognitive processes contribut-
ing to depression. Specifically, the cognitive patterns measured in this
study are noted to predict and are associated with depression (Antypa
et al., 2010; Moulds et al., 2008); implications for future research are
that a longer trial may reveal differences between groups in depres-
sive symptoms as changes in cognition translate to changes in mood
over time. Interestingly, follow-up analyses indicated that one month af-
ter completing the intervention, participants in the probiotics but not
placebo group were more likely to move from a subclinical diagnosis
to no depression diagnosis. In particular, participants in the severe pro-
biotics group showed a significant change in diagnostic level from pre
to follow-up assessment with a tendency to move from a clinical to a
subclinical diagnosis over these time points. One account for these fol-
low-up findings is that as suggested earlier, the effect of probiotics may
present over a longer time period than the 8-week intervention period.
A longer trial may be needed to more fully assess the effect of probiotics
on mood. Yet, there is no consensus on how long a probiotic trial should
run (Wallace and Milev, 2017). Alternatively, the reported changes may
be more reflective of natural or spontaneous recovery with time.
Taken together, the results of the current study and that of Steen-
bergen and colleagues indicate that the impacts of probiotics may be
more prominent in individuals with lower levels of depression sever-
ity (Steenbergen et al., 2015). Further research is needed into qualita-
tive and quantitative differences between individuals with mild/moder-
ate and severe levels of depression, the potential impact of probiotics
for varying severity levels, and the utility of probiotics as a preventative
measure for depression.
In general, no significant differences in the feacal microbiota were
observed between pre- and post-intervention subjects, in either probi-
otic or placebo groups. However analysis revealed a significant positive
correlation between one OTU, R. gnavus and the DASS depression score.
No other depression microbiota study has reported R. gnavus to be as-
sociated with depression, conversely; one microbiota study found the
Ruminococcus genera decreased in depressed populations (Jiang et al.,
2015). In contrast, R. gnavus was observed to be increased in Crohn's
disease (Joossens et al., 2011). In vitro R. ganvus produces ß-Glu-
curonidase, which is involved in toxin generation that could contribute
to local inflammation (Beaud et al., 2005). However, the relative abun-
dance of this OTU is very low so the biological significance is unclear,
further testing is required to establish if this bacterium plays a role in
depression. There is current contention on whether probiotic treatments
do successfully alter microbiota composition (e.g. (Cha et al., 2012;
Kristensen et al., 2016)). However, probiotics have been shown to mod-
ulate gut microbiota gene expression in the absence of compositional
changes, with potential anti-inflammatory effects (Eloe-Fadrosh et al.,
2015). This is one potential mechanism by which probiotics may af-
fect cognitive function. Alternatively, probiotic bacterial species may
exert effect on the host directly, as Ecologic® Barrier probiotics have
been shown in vitro to improve gut barrier function (Van Hemert and
Ormel, 2014).
The dosage size of the probiotic may not have been sufficient to
be detected in the stool but still have resulted in the psychological ef-
fects seen in the study. For example, it was shown that probiotic supple-
mentation of Lactobacillus rhamnosus GG at 10⁠8 CFU was detectable in
only 1 of 10 faecal samples, however this same strain at a higher
dose of 10⁠12 CFU was detected in all 10 faecal samples (Saxelin et al.,
1995). The dose used in this study (10⁠10 cfu/day) is above the min-
imum dose requirement for probiotics without strain specific claims
(Hill et al., 2014), and the probiotic supplementation was double that
of the dose used with healthy controls in Steenbergen et al. (2015). Fur-
ther research using a range of concentrations in a dose response study
may be warranted to determine the optimal dose. Potentially, a greater
dose, or longer consumption of probiotics would have produced a de-
tectable change in gut microbiota, as well as further differences in psy-
chological data between probiotic and placebo groups.
When comparing the gut microbiota of depressed individuals be-
fore intervention with a non-depressed cohort there were no signifi-
cant differences between groups, inconsistent with previous literature
(Jiang et al., 2015; Kelly et al., 2016; Lin et al., 2017; Naseribafrouei
et al., 2014; Zheng et al., 2016). This may be due to differences in
the populations surveyed in terms of geography and diet, which have
been shown to have an impact on the gut microbiota (Mueller et al.,
2006), or differences in inclusion/exclusion criteria. It is important to
note that all previous studies exploring differences in the gut micro-
biota in depressed humans included many depressed participants tak-
ing antidepressant medications. Some antidepressants have been shown
to be anti-microbial, and any form of medication is a confounding fac-
tor in a gut microbiota study (Ayaz et al., 2015; Coban et al., 2009;
Devkota, 2016; Kristiansen, 1990; Kruszewska et al., 2012; Lieb, 2004;
Munoz-Bellido et al., 2000). In this study, participants were excluded if
they took any type of medication that could influence mood or gut func-
tioning (including antidepressants), and no changes in the gut micro-
biota were observed. Further investigation into microbiota associations
with depression in humans should be undertaken which specifically con-
siders possible confounding factors such as medication.
One of the major limitations of this study is the attrition rate of 34%.
Aside from occurrences where patients were removed for no longer
meeting inclusion/exclusion criteria (for instance taking medications
during the trial), the cause of the high attrition rate was most likely
due to the requirement for depressed participants to attend weekly
monitoring visits. Similar probiotic studies where weekly visits were
not required had lower attrition rates (Rao et al., 2009; Romijn et al.,
2017). Further, increasing the frequency of visits in clinical trials of
antidepressants has been associated with higher attrition rates in de-
pressed populations (Rutherford et al., 2013). Additionally, non-compli-
ance to medical treatment recommendations is much more likely in de-
pressed cohorts compared to non-depressed patients (DiMatteo et al.,
2000), thus, they are more likely to drop-out of clinical trials. In the
current study, weekly visits were implemented due to ethics board re-
quirements for weekly participant safety monitoring, with utilisation of
intention-to-treat analysis to diminish attrition bias (Jüni et al., 2001;
May et al., 1981; Sackett and Gent, 1979). However, future research
should consider alternative monitoring methods such as Skype or phone
reviews, rather than face-to-face.
Overall, this study offers evidence to indicate that probiotic con-
sumption can exert change on cognitive patterns associated with de-
pression. The study may have benefitted from the inclusion of more
sensitive measures of physiological stress, such as cortisol analysis of
urine, saliva or blood samples to complement participant's self-report
scores. Nevertheless, these preliminary results are promising and of-
fer a number of future research and clinical avenues to build upon.
For instance, future research would benefit from additional analysis
methods to investigate specific gut microbiota strains, as well as ex-
amination of how to maximise the benefits of probiotics, for example
dosages and timeframes. In clinical practice, probiotics may be a use-
ful adjunct to potentiate the effects of therapies, such as CBT, which
involves changing cognitive patterns. Finally, the use of probiotics pro-
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treatment; this holistic view may be a perspective that greatly improves
treatment acceptability for individuals with depression.
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